ADMA Biologics, Inc.
ADMA
$20.11
$0.391.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.00% | 13.80% | 40.22% | 59.06% | 78.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.00% | 13.80% | 40.22% | 59.06% | 78.13% |
| Cost of Revenue | -2.63% | 10.09% | 25.58% | 33.15% | 41.19% |
| Gross Profit | 26.76% | 17.01% | 56.23% | 90.84% | 141.99% |
| SG&A Expenses | 17.71% | 33.14% | 52.40% | 58.47% | 28.88% |
| Depreciation & Amortization | 35.71% | -77.46% | -87.05% | -86.63% | -84.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.75% | 16.47% | 33.08% | 39.31% | 36.89% |
| Operating Income | 28.69% | 9.18% | 59.85% | 124.99% | 356.40% |
| Income Before Tax | 29.30% | 11.84% | 81.78% | 296.73% | 1,332.71% |
| Income Tax Expenses | 1,219.88% | 55.13% | 1,000.17% | -- | -- |
| Earnings from Continuing Operations | 1.45% | 6.73% | 51.10% | 734.15% | 1,299.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.45% | 6.73% | 51.10% | 734.15% | 1,299.96% |
| EBIT | 28.69% | 9.18% | 59.85% | 124.99% | 356.40% |
| EBITDA | 27.56% | 8.75% | 53.96% | 110.36% | 285.80% |
| EPS Basic | -0.26% | 2.76% | 45.37% | 706.02% | 1,242.98% |
| Normalized Basic EPS | 32.99% | 10.79% | 75.10% | 203.51% | 1,278.87% |
| EPS Diluted | 0.00% | 7.69% | 41.39% | 676.07% | 1,400.00% |
| Normalized Diluted EPS | 35.29% | 12.11% | 75.72% | 192.01% | 1,259.42% |
| Average Basic Shares Outstanding | 1.72% | 3.90% | 3.89% | 4.63% | 4.13% |
| Average Diluted Shares Outstanding | -0.06% | 2.66% | 3.49% | 8.82% | 4.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |